Myriad Advances MRD Commercialization with New Study Data

Myriad Genetics announced a commercialization roadmap for its Precise MRD assay, which will launch in March 2026 for breast cancer, followed by colorectal and renal cancers later this year. The assay detects circulating tumor DNA at extremely low levels and has shown a clear link to clinical outcomes. Interim study analyses have suggested near-universal baseline detection and recurrence prediction in colorectal cancer, as well as high baseline sensitivity in breast cancer.